Date: 11 Dec 2012
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Roxithromycin is a derivative of the macrolide antibacterial erythromycin with in vitro antibacterial activity resembling that of the parent compound. The drug has activity against some Staphylococcus spp., many Streptococcus spp., Moraxella (Branhamella) catarrhalis, Mycoplasma pneumoniae, Legionella pneumophila and Chlamydia trachomatis as well as many less common organisms. Measured using recently proposed guidelines, roxithromycin has in vitro activity against Haemophilus influenzae. In comparison with that of its parent compound, the pharmacokinetic profile of roxithromycin is characterised by high plasma, tissue and body fluid concentrations and a long half-life permitting an extended dosage interval.
Roxithromycin has proven clinical efficacy in upper and lower respiratory infections, skin and soft tissue infections, urogenital infections and orodental infections, and appears to be as effective as more established treatments including erythromycin, amoxicillin/clavulanic acid and cefaclor. The drug has also shown promise in a variety of more specialised indications including opportunistic infections in human immunodeficiency virus (HlV)-positive patients and as part of a Helicobacter pylori eradication regimen. Roxithromycin is very well tolerated with an overall incidence of adverse events of approximately 4%.
Thus, roxithromycin is an attractive therapeutic alternative in its established indications, especially when the option of once-daily administration is considered.
Roxithromycin is an ether oxime derivative of erythromycin with in vitro activity resembling that of the parent compound. MIC90 (minimum concentration required to inhibit 90% of strains) values of ≤2 mg/L and 2 to 4 mg/L are indicative, respectively, of full and moderate susceptibility to the drug. Roxithromycin has variable activity against methicillin-susceptible Staphylococcus aureus but methicillin-resistant S. aureus, as well as S. epidermidis, S. haemolyticus and S. hominis, are not susceptible to the drug. Erythromycin-susceptible isolates of coagulase-negative staphylococci are susceptible to roxithromycin but erythro-mycin-resistant isolates are not.
Roxithromycin is active against Streptococcus agalactiae, S. pneumoniae, S. pyogenes, Lancefield group C and viridans group streptococci. It is generally inactive against Lancefield group G Streptococcus and enterococci. The activity of roxithromycin against Listeria monocytogenes is broadly similar to that of erythromycin, with most isolates being inhibited at a concentration of 1 or 2 mg/L.
Roxithromycin MIC90 values for Neisseria gonorrhoeae are similar to those of erythromycin; Neisseria meningitidis is slightly less susceptible with an MIC range of 0.3 to 4 mg/L.
Roxithromycin has borderline activity in vitro against Haemophilus influenzae when measured using current susceptibility guidelines; however, a higher susceptibility breakpoint of ≤16 mg/L has recently been proposed. The drug has good in vitro activity against Bordetella pertussis, B. parapertussis, Borrelia burgdorferi, Moraxella catarrhalis and Legionella pneumophila. Roxithromycin MIC90 values against Chlamydia trachomatis range between 0.25 and 1 mg/L.
Roxithromycin had an MIC90 value of 16 mg/L against 28 Mycobacterium avium complex strains isolated from patients with acquired immune deficiency syndrome, compared with values of 8, 32 and ≥64 mg/L for clarithromycin, azithromycin and erythromycin, respectively.
Roxithromycin MIC90 values against Bacteroides spp. and Clostridium difficile are high.
Roxithromycin exerts its action by disrupting bacterial protein synthesis. It is also concentrated in human polymorphonuclear leucocytes and macrophages. The drug has demonstrated good activity in animal models of Gram-positive and other infections such as toxoplasma encephalitis, Legionnaires’ disease, Mycobacterium leprae infection, syphilis and chlamydial urogenital infection.
The pharmacokinetic profile of roxithromycin differs substantially from that of its parent compound, erythromycin.
Mean plasma roxithromycin concentrations ranging between 6.6 and 7.9 mg/L are achieved within 2 hours after administration of a single oral 150mg dose. In a direct comparison, the area under the plasma concentration versus time curve produced by roxithromycin 150mg was 16.2-fold greater than that produced by erythromycin 250mg. Multiple doses produced similar differences. The drug is strongly, specifically and saturably bound to a 1-acid glycoprotein in plasma. The plasma clearance of roxithromycin appears to be dose- or plasma concentration-dependent. Concentrations achieved in tissues and body fluids are generally higher than MIC90 values for susceptible organisms. In a study assessing elimination, 74.2% of a radiolabeled roxithromycin dose was accounted for: 53.4% in faeces; 13.4% as expired carbon dioxide and 7.4% in the urine.
The mean elimination half-life of roxithromycin (8.4 to 15.5 hours) is much longer than that recorded for erythromycin (1.5 to 3 hours). Its pharmacokinetics appear to be nonlinear and may include a saturable process involving plasma a 1-acid glycoprotein releasing bound drug for distribution and elimination.
The pharmacokinetic profile of roxithromycin in children is generally similar to that in adults. Dosage adjustment is not required in the elderly or in patients with renal impairment.
Roxithromycin has produced efficacy rates of between 71 and 96% in patients with tonsillitis or sinusitis and resolved or improved the signs and symptoms of pharyngotonsillitis and sinusitis significantly more effectively than clarithromycin in 1 study.
Clinical efficacy rates were >90% in almost 10 000 patients with acute bronchitis who received roxithromycin in noncomparative studies. The clinical efficacy of roxithromycin was very similar to that of amoxicillin/clavulanic acid, cefaclor and azithromycin in comparative studies. Roxithromycin is also an effective treatment for exacerbations of chronic bronchitis, producing clinical efficacy rates ranging between 83.3 and 89% in 4 noncomparative trials involving >4000 patients, and having clinical efficacy similar to that of amoxicillin/clavulanic acid, oxycycline, cefaclor and azithromycin in comparative studies.
Roxithromycin has demonstrated similar clinical efficacy to amoxicillin/clavulanic acid, azithromycin, clarithromycin, cefaclor, erythromycin and midecamycin acetate in patients with pneumonia. The drug is also an effective treatment for patients with pneumonia caused by atypical organisms such as chlamydia, mycoplasma, Legionella spp., rickettsia and Coxiella burnetii.
Roxithromycin 300 mg/day was equally effective administered either once or twice daily to 1588 patients with various infections.
One study has shown roxithromycin to be as effective as josamycin as treatment for patients with suppurative skin and soft tissue infections and as effective as penicillin in patients with erysipelas.
The clinical efficacy of roxithromycin was similar to that of amoxicillin, erythromycin and josamycin as treatment for orodental and odontological infections and was also comparable with spiramycin as prophylaxis prior to dental surgery.
In patients with urogenital or gynaecological infections, roxithromycin has produced clinical response rates ranging between 71 and 100%, and was as effective as doxycycline and minocycline in comparative studies. The drug was equally effective administered either once or twice daily in patients with nongonococcal urethritis.
Roxithromycin has good in vitro activity against Borrelia burgdorferi and, in combination with cotrimoxazole (trimethoprim/sulfamethoxazole), was an effective treatment for late Lyme disease. In a pilot study the drug effectively prevented pneumocystosis and cerebral toxoplasmosis in human immunodeficiency virus (HlV)-positive patients, either alone or in combination with pentamidine aerosol. Roxithromycin 300 mg/day in combination with omeprazole and bismuth subni-trate eradicated confirmed Helicobacter pylori infection in patients with peptic ulcers and gastritis more effectively than omeprazole monotherapy.
Although recent paediatric studies are limited, roxithromycin 5 to 10 mg/kg/day has demonstrated efficacy in the treatment of respiratory tract and skin and soft tissue infections in children and, compared with placebo, has significantly reduced the duration of diarrhoea and faecal excretion of Campylobacter in children with campylobacter-associated enteritis.
Gastrointestinal symptoms are the most common adverse events during roxithromycin therapy. Large noncomparative studies have reported an overall incidence of adverse events of around 4%, with gastrointestinal symptoms accounting for 75 to 80% of these. The overall incidence of adverse events in patients treated with roxithromycin has compared favourably with those of other antibacterial drugs and appears to be lower than that of erythromycin. The adverse event profile of the drug in children is similar to that in adults.
Isolated cases of cholestatic hepatitis and 1 case of fulminant acute hepatitis have been reported in patients receiving roxithromycin.
The drug appears to have less effect on gastrointestinal motility and faecal bacterial flora than erythromycin.
Dosage and Administration
Roxithromycin 300 mg/day, administered once-daily or in 2 divided doses, is the recommended adult dosage for all indications. The recommended dose for infants and children is 5 to 8 mg/kg body weight per day administered in 2 divided doses. The drug should be given at least 15 minutes before food. A 50% dosage reduction has been recommended for patients with hepatic insufficiency. Dosage modifications are not required in elderly patients or in patients with renal insufficiency.
Various sections of the manuscript reviewed by: B.A Brown, Department of Microbiology, University of Texas Healthcenter at Tyler, Tyler, Texas, USA; M. Casal Roman, Department of Medical Microbiology, Faculty of Medicine, Cordoba University, Cordoba, Spain; M. Del Tacca, Faculty of Medicine and Surgery, Institute of Pharmacology, University of Pisa, Pisa, Italy; R.G. Finch, Department of Microbial Diseases, Nottingham City Hospital, Nottingham, England; FW. Goldstein, Service de Microbiologie Médicale, Hôpital Saint-Joseph, Paris, France; D.R.R Guay, Section of Clinical Pharmacy, St Paul-Ramsey Medical Center, St Paul, Minnesota, USA; K.G. Kerr, Department of Microbiology, University of Leeds, Leeds, England; P. Le Noc, Laboratoire de Bactériologie et Virologie, Faculté de Médecine de Grenoble, Université Joseph Fourier, Grenoble, France; P. Lidbrink, Department of Dermato-Venereology, Huddinge Hospital, Huddinge, Sweden; O. Paulsen, Department of Infectious Diseases, Malmö General Hospital, University of Lund, Malmö, Sweden; N.A. Peterslund, Department of Medicine and Hematology, Aarhus University Hospital, Aarhus, Denmark; JR. Soejima, Kawasaki Medical School, Okayamu, Japan; M. W. Tilyard, Department of General Medicine, Otago Medical School, University of Otago, Dunedin, New Zealand; R.J. Wallace, Department of Microbiology, University of Texas Healthcenter at Tyler, Tyler, Texas, USA
Jones RN. Disk diffusion susceptibility testing of macrolides: the interpretive criteria. In: Bryskier AJ, Butzler J-P, Neu HC, et al., editors. Macrolides: chemistry, pharmacology and clinical uses. Paris: Arnette Blackwell, 1993: 209–15
Barry AL, Thornsberry C, Jones RN. In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin and clindamycin. Antimicrob Agents Chemo ther 1987; 31: 343–5CrossRef
Casal Roman M, Gutierrez Aroca J, Ruiz Martinez P, et al. In vitro activity of macrolides alone and in combination with antituberculous compounds against Mycobacterium tuberculosis. Rev Esp Quimioter 1990; 3: 69–72
Chardon H, Bellon O, Bourgeous F, et al. Comparative in vitro activity of five macrolides against 190 strains of Branhamella catarrhalis [in French]. Pathol Biol 1989; 37: 382–5PubMed
Dailloux M, Villemain P. Bacteriostatic and bactericidal activities of cyclines, macrolides, and fluoroquinolones against Chlamydia trachomatis. Pathol Biol 1992; 40: 455–60PubMed
Dutilh B, de Barbeyrac B, Lafferrière C, et al. Activité comparée in vitro d’un nouveau macrolide RU 28965 et de l’eryth-romycycine vis-à-vis de Chlamydia trachomatis. Pathol Biol 1986; 34: 445–7PubMed
Felmingham D, Robbins MJ, Sanghrajka M, et al. The in vitro activity of some 14-, 15- and 16- membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum. Drugs Exp Clin Res 1991; 17: 91–9, No. 1
Ferreruela RM, Alcaraz MJ, Farga MA, et al. Activity of new macrolides against genitourinary and respiratory mycoplasmas. Rev Esp Quimioter 1991; 4: 209–15
Loza E, Martinez Beltrán J, Baquero F, et al. Comparative in vitro activity of clarithromycin. New Antimicrobial Agents 1992; 11: 856–66
Rolston KV, Ho DH, LeBlanc B. Comparative in vitro activity of the new erythromycin derivative dirithromycin against Gram-positive bacteria isolated from cancer patients. Eur J Clin Microbiol 1990; 9: 30–3CrossRef
Le Noc P, Croize J, Bryskier A, et al. Comparative in vitro bacteriostatic and bactericidal activities of five macrolides (roxithromycin, erythromycin, troleandomycin, josamycin, spiramycin) against 284 hospital bacterial strains [in French]. Pathol Biol 1989; 37: 553–9PubMed
Suermondt G, Denamur E, Fleuret A, et al. In vitro activity of miocamycin compared with pristinamycin and four macrolides on B. catarrhalis (French). Pathol Biol 1989; 37: 386–9PubMed
Fleurette J, Bornstein N. Susceptibility of Legionella species to roxithromycin [abstract]. 15th International Congress of Chemotherapy; 1987 Jul 19–24: Istanbul
Fournet M-P, Zini R, Deforges L, et al. Determination of binding parameters of macrolides, lincosamides, and streptogramins to Legionella pneumophila. J Pharm Sei 1987; 76: 153–6CrossRef
Jones RN, Erwin ME. Review of the anti-legionella activity of roxithromycin and the use of the E-test to determine potency [abstract]. Second International Conference on the Macrolides Azalides and Streptogramins; 1994 Jan 19–22; Venice
Acar JF, Goldstein FW. In vitro activity against Gram-positive and Gram-negative bacteria. In: Neu HC, Young LS, Zinner SH, editors. The new macrolides, azalides and streptogramins. Pharmacology and clinical applications. New York: Marcel Dekker, Inc., 1993: 13–24
Tomé G, Goldberg M, Jugo M, et al. Bacteriostatic and bactericidal activity of roxithromycin against H. influenazae (Hi) isolated from patients suffering respiratory tract infections (RTI) [abstract]. Second International Conference on the Macrolides Azalides and Streptogramins; 1994 Jan 19–22; Venice
Struelens MJ, Nonhoff C, Lontie M, et al. In vitro activity of commonly used oral antimicrobial agents against community isolates of respiratory pathogens. Acta Clin Belg 1991; 46: 283–9PubMed
Soussy CJ, Chanal M, Kitzis MD, et al. In vitro antibacterial activity of roxithromycin for hospital bacteria and regression curve [in French]. Pathol Biol 1988; 36: 420–4PubMed
Barlam T, Neu HC. In vitro comparison of the activity of RU28965. a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria. Antimicrob Agents Chemo ther 1984; 25: 529–31
Casellas JM, Goldberg M, Arduiros S, et al. Comparative MIC and MBC of roxithromycin, A56286 and erythromycin against 600 clinical isolates [abstract]. 15th International Congress of Chemotherapy; 1987 Jul 19–24
Croize J, Le Noc P, Bryskeir A, et al. Activité in vitro de trois macrolides: érythromycine, josamycine et roxithromycine vis-a-vis de 349 bactéries aérobies ou anaérobies. Bordeaux Médical 1987; 20: 159–62
King A, Phillips I. The in vitro activity of roxithromycin, a new macrolide antibiotic, in comparison with that of erythromycin. Drugs Exp Clin Res 1987; 13: 563–6PubMed
Tsuboi Y, Sakoda T, Mitsuhashi S. In vitro and in vivo antibacterial activity of roxithromycin. Br J Clin Pract 1988; 42 Suppl. 55: 30–2
Preac-Mursic V, Wilske B, Schierz G, et al. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi. European Journal of Clinical Microbiology and Infectious Disease 1989; 8: 651–3CrossRef
Gasser R, Reisinger E, Klein W. Combined therapy with roxithromycin and co-trimoxazole of late Lyme disease [abstract no. 5103]. 18th International Congress of Chemotherapy; 1993 Jun 27–Jul; Stockholm: 401
Hansen K, Hovmark A, Lebech A-M, et al. Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm Venereol 1992; 72: 297–300PubMed
Sambri V, Massaria F, Cevenini R, et al. In-vitro susceptibility of Borrelia burgdorferi and Borrelia hermsii to ten antimicro bial agents. J Chemother 1990; 2: 348–50PubMed
Marelli P, Di Campli E, Campa M, et al. In vitro activity of macrolides and omeprazole against Helicobacter pylori [ab-stract no. 265]. 6th European Congress of Clinical Microbiology and Infectious Diseases; 1993 Mar 28–31; Seville, 1993
Casai M, Rodriguez F, Villalba R, et al. In vitro usceptibility of Mycobacterium avium-complex against rifabutin (LM 427) alone and in combination with amikacin, roxithromycin and ethambutol. Rev Esp Quimioter 1990; 3: 87–9
Rastogi N, Seng Goh K, Bryskier A. Activity of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin and clofazimine against the Mycobacterium avium complex [abstract]. Second International Conference on the Macrolides Azalides and Streptogramins; 1994 Jan 19–22; Venice
Brown BA, Wallace Jr RJ, Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonaelike organisms. Antimicrob Agents Chemother 1992; 36: 180–4CrossRef
Cevenini R, Rumpianesi F, Sambri V, et al. In vitro activity of RU 28965, a new macrolide, against Chlamydia trachomatis and Ureaplasma urealyticum. In Butzler & Kobayashi (Eds) 1986.; Macrolides: a review with an outlook on future developments, p. 125–127, Excerpta Medica, Amsterdam
Rumpianesi F, Morandotti G, Sperning R, et al. In vitro activity of azithromycin against Chlamydia trachomatis, Ureaplasma urealyticum and Mycoplasma hominis in comparison with erythromycin, roxithromycin and minocycline. J Chemother 1993; 5: 155–8PubMed
Cuffini AM, Tullio V, Cimino F, et al. Comparative effects of roxithromycin and erythromycin on cellular immune functions in vitro. 1 uptake of 3H-macrolides by human macrophages. Microbios 1989; 57: 167–78
Fietta A, Boeri P, Colombo ML. Bioactivity of flurithromycin and other macrolides against intracellular susceptible staphylococci. Chemotherapy Basel 1993; 39: 48–54CrossRef
Torigoe R. The intracellular activity of ofloxacin and roxithromycin against Staphylococcus aureus phagocytosed in human neutrophils. Chemotherapy Tokyo 1993; 41: 955–62
Rolin O, Bouanchaud DH. Comparison of in vitro post-antibiotic effect induced by 14-membered-ring macrolides (erythromycin and roxithromycin) and 16-membered-ring macrolides (josamycin and spiramycin) in Staphylococcus aureus [in French]. Pathol Biol 1989; 37: 375–7PubMed
Moneib NA, Shibl AM, El-Said MA, et al. Macrolides induced suppression of virulence factors produced by Staphylococcus aureus. J Chemother 1993; 5: 289–92PubMed
Paulsen O. Roxithromycin — a macrolide with improved phar macokinetic properties. Drugs Today 1991; 27: 193–222
Carlone NA, Cuffini AM, Tullio V, et al. Comparative effects of roxithromycin and erythromycin on cellular immune functions in vitro. 2 Chemotaxis and phagocytosis of 3-Staphylococcus aureus by human macrophages. Microbios 1989; 58: 17–25
Satake N, Nagai S, Nishimura K, et al. The effect of roxithromycin (RXM, erythromycin derivative) on blood neutrophil mobility toward FMLP in patients with diffuse bronchiectasis and idiopathic pulmonary fibrosis. Eur Respir J 1992; 5 Suppl. 15: 142
Akamatsu H, Sasaki H, Matoba Y, et al. Effects of roxithromycin on neutrophil Chemotaxis and phagocytosis in vitro. Ensho 1994; 14: 59–65CrossRef
Lianou PE, Bassaris HB, Vlachodimitropoulos D, et al. Inter actions of subinhibitory concentrations of roxithromycin with Gram-positive bacteria [abstract]. 16th International Congress of Chemotherapy; 1989 Jun 11–16: Jerusalem
Fitzgeorge RB, Featherstone ASR. Roxithromycin therapy of experimental Legionnaires’ disease. Correspondence. J Antimicrob Chemother 1989; 23: 462–3CrossRef
Jayais P, Pangon B, Valois JM, et al. Activity of roxithromycin in prophylactic treatment of experimental Staphylococcus aureus endocarditis [abstract]. 16th International Congress of Chemotherapy; 1989 Jun 11–16: Jerusalem: 108
Luft BJ, Hofflin J, Chen J, et al. The activity of RU 28965, a macrolide, in the treatment of toxoplasmic encephalitis [abstract]. Interscience Congress on Antimicrobial Agents and Chemotherapy; 1986; New Orleans
Chang HR, Pechère JC. Activity of the combination of pyrimethamine plus roxithromycin on Toxoplasma gondii in mice. 16th International Congress of Chemotherapy; 1989 Jun 11–16: Jerusalem: 22
Kees F, Grobecker H, Fourtillian JB, et al. Comparative pharmacokinetics of single dose roxithromycin (150mg) versus erythromycin stéarate (500mg) in healthy volunteers. Br J Clin Pract 1988; 42 Suppl. 55: 51
Zini R, Fournet MP, Barre J, et al. In vitro study of roxithromycin binding to serum proteins and erythrocytes in humans. Br J Clin Pract 1988; 42 Suppl. 55: 54
Lassman HB, Puri SK, Ho I, et al. Pharmacokinetics of Roxithromycin (RU 965). J Clin Pharmacol 1988; 28: 141–52PubMed
Tremblay D, Meyer B, Saint-Salvi B, et al. Influence of food on bioavailability of roxithromycin (RU 28 965). Acta Phar-acologica et Toxicologica 1986; 59 Suppl. 5: 191
Anonymous. Roxithromycin prescribing information. Australia
Acar JF, Saint-Salvi B, Blanc F. Concentration of roxithromycin in tear fluid and saliva after repeat dosing. Br J Clinract 1988; 42 Suppl. 55: 82
Begue P, Lacome H, Cotin G, et al. Diffusion of roxithromycin into tonsillar tissue in children. Br J Clin Pract 1988; 42 Suppl. 55: 78–9
Botto H, Carney M, Chretien P, et al. Study of the diffusion of roxithromycin into prostatic tissue after repeat oral dosing. Br J Clin Pract 1988; 42 Suppl. 55: 83
De Grandi P, Comte R, Von Moos G, et al. Concentration of roxithromycin in plasma and gynaecological tissues following repeated oral administrations. Br J Clin Pract Symp Suppl 1988; 42 Suppl. 55: 84–5
Kafetzis DA, Ligatsikas C, Saint-Salvi B, et al. Concentrations of roxithromycin in tonsil and adenoid tissues after single and repeated administrations to children. Br J Clin Pract 1988; 42 Suppl. 55: 80
Meirovich CI, Monkrull H, Strusberg AM, et al. Roxithromycin levels in synovial fluid. Br J Clin Pract 1988; 42 Suppl. 55: 88
Rimoldi R, Mangiarotti P, De Rose V, et al. Penetration of roxithromycin into bronchial secretions. Br J Clin Pract 1988; 42 Suppl. 55: 74–7
Tremblay D, Mignot A, Couraud L, et al. Concentrations of roxithromycin in lung tissue after repeat dosing. Br J Clin Pract 1988; 42 Suppl. 55: 73
Boccazzi A, Langer M. Penetration of roxithromycin into bronchial secretions. Chemotherapy Basel 1991; 37: 303–9CrossRef
Vandeghen P, Smets P, Gerardy B, et al. Penetration of roxithromycin into the gastric mucosa [abstract]. 16th International Congress of Chemotherapy; 1989 Jun 11–16: Jerusalem: 222
Del Tacca M, Danesi R, Bernadini N, et al. Roxithromycin penetration into gingiva and alveolar bone of odontoiatric patients. Chemotherapy Basel 1990; 36: 332–6CrossRef
McLean A, Sutton JA, Salmon J, et al. Roxithromycin: pharmacokinetic and metabolism study in humans. Br J Clin Pract 1988; 42 Suppl. 55: 52–3
Tremblay D, Jaeger H, Fourtillan JB, et al. harmacokinetics of three single doses (150, 300, 450mg) of roxithromycin in young volunteers. Br J Clin Pract 1988; 42 Suppl. 55: 49–50
Boccazzi A, Mezzopane A, Maffezzoli M, et al. Roxithromycin in paediatrics: pharmacokinetics and clinical efficacy of a single daily dose. 16th International Congress of Chemotherapy; 1989 Jun 11–16; Jerusalem, 220
Demotes-Mainard FM, Vincon GA, Albin HC. Pharmacokinetics of a new macrolide, roxithromycin, in infants and children. J Clin Pharmacol 1989; 29: 752–6PubMed
Roussel Uclaf. Roxithromycin prescribing information. Romainville, France
Höffler D, Koeppe P, Sörgel F, et al. The pharmacokinetics of roxithromycin in dialysis patients. 18th International Congress of Chemotherapy; 1993 Jun 27–Jul 2; Stockholm, 260
Babany G, Roulot D, Chrétien P, et al. Pharmacokinetics of single and repeated oral doses of roxithromycin in patients with cirrhosis [abstract]. 16th International Congress of Chemotherapy; 1989 Jun 11–16: Jerusalem: 222
Fritz J, Fourie E, Pickard I, et al. A randomised controlled study of oral roxithromycin and amoxicillin plus clavulanic acid in the treatment of patient with acute maxillary sinusitis. 17th International Congress of Chemotherapy; 1991 Jun 23–28; Berlin
Higuera-Ramirez F, Hidalgo H. Multicentre study of the efficacy and tolerability of roxithromycin in the treatment of respiratory tract infections. Drug Invest 1991; 3 Suppl. 3: 38–46CrossRef
Manzini M, Caroggio A. Efficacy and tolerability of brodimoprim and roxithromycin in acute sinusitis of bacterial origin in adults. J Chemother 1993; 5: 521–5PubMed
Saldarriaga A. Roxithromycin 150 mg bid in the treatment of sinusitis [abstract]. Second International Conference on the Macrolides Azalides and Streptogramins; 1994 Jan 19–22; Venice
Sanchez L. Roxithromycin in the treatment of pharyngotonsill-itis. Second International Conference on the Macrolides Azalides and Streptogramins; 1994 Jan 19–22; Venice
Saenghirunvattana S. Treatment of outpatients with community-acquired pneumonia with roxithromycin. J Med AssocThai 1992; 75: 283–6
Scott WG, Cooper BC, Scott HM, et al. Roxithromycin vs amoxycillin/clavulanic acid for community treated lower respiratory tract infection. A pharmacoeconomic study [abstract]. Second International Conference on the Macrolides Azalides and Streptogramins; 1994 Jan 19–22; Venice
Sliman NA. Roxithromycin in empiric five day treatment of respiratory tract infections [abstract no. 82]. 18th International Congress of Chemotherapy; 1993 Jun 27–Jul 2; Stockholm: 136
Laurent K. Efficacy, safety and toleration of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections [abstract]. Second International Conference on the Macrolides Azalides and Streptogramins; 1994 Jan 19–22; Venice
Mühlbacher J, Ridl W, Sarffy-Panosch B, et al. Josamycin (J) in comparison to clari- (C) and roxithromycin (R) in the treatment of bronchitis [abstract no. 250]. Second International Conference on the Macrolides Azalides and Streptogramins; 1994 Jan 19–22; Venice
Champetie de Ribes D, Jockey C, Gaudouen G. A study of the effectiveness and tolerance of roxithromycin in lower respiratory tract infections. Sem Hop 1989; 65: 2819–21
Brambilla C. A multicentre study to evaluate the efficacy and safety of roxithromycin (once a day) vs erythromycin in the treatment of community-acquired pneumonia. 18th International Congress of Chemotherapy; 1993 Jun 27–Jul 2; Stockholm, 352
Soejima R, Niki Y, Hino J, et al. Double-blind comparative study of roxithromycin (RU 28965) and midecamycin acetate (MOM) in the treatment of pneumonia. Kansenshogaku Zasshi 1990; 63: 501–29
Stamboulian D, Perianu M. The efficacy of roxithromycin (300 mg once daily or 150 mg BID) in the treatment of “atypical” pneumonia in an international multicentre study. 17th International Congress of Chemotherapy; 1991 Jun 23–28; Berlin
Schönwald S, Car V, Kuzman I, et al. Comparison of Rulid (Roxithromycin) and erythromycin in the treatment of atypical pneumonias [abstract]. 16th International Congress of Chemotherapy; 1989 Jun 11–16, Jerusalem
Cooper BC, Mullins PR, Jones MR, et al. Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infections due to Haemophilus influenzae. Ameta-analysis of 12 clinical studies. Drug Invest 1994; 7: 229–314
Nohara N, Akagi M, Kanzaki H. Comparative double blind test of roxithromycin and josamycin on purulent diseases. Chemotherapy Tokyo 1989; 37: 1518–9
Badile S, Bruno E, Porcellini A, et al. Roxithromycin in odontologie infections. 16th International Congress of Chemotherapy; 1989 Jun 11–16: Jerusalem, 222
Bercy P, Burguet J, Gossiaux T, et al. Treatment of dental infections: a double blind comparison of roxithromycin versus amoxycillin. Second International Conference on the Macrolides Azalides and Streptogramins; 1994 Jan 19–22; Venice
Panattoni E, Marcucci M, Gabriele M, et al. Clinical efficacy of roxithromycin in patients affected by acute odontogenic infections. Minerva Stomatologica 1991; 40: 273–6PubMed
Sasaki J, Morihana T. Double-blind comparison of roxithromycin and josamycin in odontogenic infections [abstract]. 16th International Congress of Chemotherapy; 1989 Jun 11–16: Jerusalem, 223
Burquet J, Smets P, Wodelet J, et al. Double-blind study comparing efficacy and tolerance of roxithromycin and spiramycin in stomatology. 16th International Congress of Chemotherapy; 1989 Jun 11–16: Jerusalem, 223
Bajares de Lilue M, Mazzali de Ilja R, Santiago A, et al. Comparative study between roxithromycin and doxycycline in mycoplasma and chlamydial gynaecological infections. Second International Conference on the Macrolides Azalides and Streptogramins; 1994 Jan 19–22; Venice
Hoyme UB, Alimi M, Feldmann HU, et al. Roxithromycin v.s. doxycycline in treatment of cervicitis. 16th International Congress of Chemotherapy; 1989 Jun 11–16: Jerusalem, 226
Lidbrink P, Bygdeman S, Emtestam L, et al. Roxithromycin compared to doxycycline in the treatment of genital chlamyd ial infection and non-specific urethritis. Int J STD AIDS 1993; 4: 110–3PubMed
Narimatsu A, Ito T, Ono M, et al. Chlamydial infections in the fields of gynecology and obstetrics [abstract no.964]. 18th International Congress of Chemotherapy; 1993 Jun 27–Jul 2; Stockholm, 283
Negosanti N, d’Antuono A. Efficacy of roxithromycin vs minocycline in the treatment of non gonococcal urethritis: clinical and microbiological aspects. 16th International Congress of Chemotherapy; 1989 Jun 11–16; Jerusalem, 252
Rosales M, Dominguez V, Bonacho I. Roxitromycine versus doxycycline in the treatment of cervicitis due to Chlamydia trachomatis in asymptomatic women. Rev Clin Esp 1993; 192: 253–5PubMed
Siboulet A. Roxithromycin in non gonococcal cervico-vaginitis [abstract]. 16th International Congress of Chemotherapy; 1989 Jun 11–16: Jerusalem; 252
Van Schouwenburg J, De Bruyn O, Heyns A, et al. A randomised, comparative study of the efficacy and tolerance of roxithromycin and doxycycline in the treatment of women with positive endocervical cultures for Chlamydia trachomatis and Ureaplasma urealyticum in an in-vitro fertilization programme. 17th International Congress of Chemotherapy; 1991 Jun 23–28; Berlin
Bircher AJ, Geizer D, Rufli T. Roxithromycin in the treatment of non-gonococcal urethritis. A double blind comparison of two treatment regimens [abstract]. 16th International Congress of Chemotherapy; 1989 Jun 11–16; Jerusalem, 226
Durant J, Hazime F, Bernard E, et al. An open randomized study of roxithromycin (RO) efficacy and tolerance in the primary prevention (PP) of pneumocystosis (PC) and cererbal toxoplasmosis (CT) in 52 HIV-positive patients [abstract no.1216]. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1991 Oct 11–14; Anaheim
Bayerdörffer E, Mannes GA, Sommer A, et al. High dose omeprazole treatment combined with amoxicillin eradicates Helicobacter pylori. Eur J Gastroenterol Hepatol 1992; 4: 697–702
Labenz J, Gyenes E, Rühl GH, et al. Efficacy of omeprazole and amoxicillin to eradicate HP. Am J Gastroenterol 1992; 87: 1271
Okamoto S, Haruma K, Kawaguchi H, et al. Study on eradication of helicobacter pylori by the combination use of roxithromycin, bismuth subnitrate, and omeprazole [abstract no. 960]. 18th International Congress on Chemotherapy; 1993 Jun 27–Jul 2; Stockholm; 1993, 282
Burette A, Glupcznski Y, Deprez C, et al. Lansoprazole plus roxithromycin and metronidazole for eradication of H. pylori results of a pilot study [abstract no. 319]. Second International Conference on the Macrolides, Azalides and Streptogramins; 1994 Jan 19–22; Venice
Bazet MC, Blanc F, Chumdermpadetsuk S, et al. Roxithromycin in the treatment of paediatric infections. Br J Clin Pract 1988; 42 Suppl. 55: 117–8
Casellas JM, Rodriguez HA, Fernandez-Macloughlin GJ, et al. Efficacy of roxithromycin in the treatment of acute otitis media in infants. Br J Clin Pract 1988; 42 Suppl. 55: 113–4
Stamboulian D, Fernandez-Macloughlin GJ, Lanoël JL, et al. Clinical evaluation of roxithromycin in 101 children. Br J Clin Pract 1988; 42 Suppl. 55: 115–6
Salvarezza C, Villar E, Ballario M. Estudio comparativo de la eficacia y tolerancia clinica de roxitromicina vs. amoxicilina en neumopatia extrahospitalarias en pediatria. Prensa Med Argent 1989; 76: 127–30
Laurencena E, Forti MJ. Roxithromycin in the treatment of acute otitis media in children. Prensa Med Argent 1992; 79: 577–9
Haentjes M, Levy J, De Boeck M, et al. Early treatment with roxithromycin of camphylobacter associated enteritis in children [abstract]. 16th International Congress of Chemotherapy; 1989 Jun 11–16, Jerusalem
Bégué P, Astruc J, Safran C, et al. The overall safety of oral roxithromycin in paediatric clinical studies [abstract]. Second International Conference on the Macrolides Azalides and Streptogramins; 1994 Jan 19–22; Venice
Dubois A, Nakache N, Raffanel C, et al. Hépatite aiguë cholestatique après prise de roxithromycine. Gastroenterol Clin Biol 1989; 13: 317–8PubMed
Delcourt A, Lambert M, Brenard R. Reversible liver injury possibly due to roxithromycin therapy. Acta Clin Belg 1990; 45: 206–7, No.3PubMed
Esteban A, Molina MJ, Soto C. Acute cholestatic hepatitis due to roxitromycine. Rev Clin Esp 1993; 192: 352–3PubMed
Pillans P, Maling T. Roxithromycin and hepatitis. Drug Invest 1993; 6: 296–9CrossRef
Anonymous. Roxithromycine et hepatite [in French]. Folia Pharmaco Therapeutica 1990; 17: 21
Souweine B, Fialaip J, Aumaitre O, et al. Acute pancreatitis associated with roxithromycin therapy. DICP 1991; 25: 1137PubMed
Wehrmann T, Rudolph U, Lembcke B, et al. Roxithromycin and erythromycin exert different effects on postprandial antroduodenal motor function and gastrointestinal symptoms inhealthy subjects. Eur J Gastroenterol Hepatol 1993; 5: 829–34
Borderon JC, Borderon E, Laugier J, et al. Effect of roxithromycin on aerobic faecal flora in children, [in French]. Pathol Biol 1989; 37: 353–7PubMed
Delaforge M, Sartori E, Mansuy D. Effects of roxithromycin on rat hepatic P-450 cytochromes: comparison with troleandomycin and erythromycin. Br J Clin Pract 1988; 42 Suppl. 55: 67–9
Delaforge M, Satori E, Mansuy D. In vivo and in vitro effects of a new macrolide antibiotic roxithromycin on rat liver cycytochrome P450: comparison with troleandomycin and erythromycin. Chemical-Biological Interactions 1988; 68: 179–88CrossRef
Villa P, Sassella D, Corada M, et al. Toxic effects of erythromycin base, estolate and RU 28965, a new macrolide, on drugmetabolizing enzymes in rat liver [abstract]. 7th International Symposium on Future Trends in Chemotherapy; 1986 May 26–28; Tirrenia
Bandera M, Fioretti M, Rimoldi R, et al. Roxithromycin and controlled release theophylline, an interaction study. Chemioterapia 1988; 7: 313–6PubMed
Backman J, Aranko K, Himberg JJ, et al. Effect of roxithromycin on pharmacokinectics and pharmacodynamics of midazolam [abstract]. 16th International Congress of Chemotherapy; 1989 Jun 11–16: Jerusalem, 189
Nilsen. Plasma pharmacokinetics of macrolides with reference to total and free concentrations. Second International Conference on the Macrolides, Azalides and Streptogramins; 1994 Jan 19–22; Venice
Volume 48, Issue 2 , pp 297-326
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors